Paolo Tarantino, 2025 Yvonne’s “Top Voice” Award Winner, Clinical Research Fellow at Dana-Farber Cancer Institute, Visiting Professor at McGill University, shared a post on LinkedIn:
“For about a decade, the standard treatment for stage II-III HER2-positive breast cancer has been neoadjuvant TCHP.
Yet, multiple signs suggest we may be moving towards a new standard. Multiple standards, actually. More tailored ones.
In this JCO editorial to the NeoCARHP phase 3 trial, I review the seismic shocks that are reshaping treatment algorithms for HER2-positive early breast cancer.”
Title: Rise and Fall of Neoadjuvant Carboplatin for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
Author: Paolo Tarantino
Read the Full Article in Journal of Clinical Oncology.
More posts featuring Paolo Tarantino.